Something Old and Something New About Molecular Diagnostics in Gliomas

Craig Horbinski*

*Corresponding author for this work

Research output: Contribution to journalReview articlepeer-review

7 Scopus citations


Progress in understanding the molecular biology of neoplasms has been driven by remarkable improvements in molecular biology techniques, creating a rapidly moving field in which even subspecialists struggle to keep abreast. Nowhere is this more clearly demonstrated than in neuro-oncology, wherein molecular diagnostics can wring more clinically useful information out of small biopsies than ever. The biologic and practical aspects of 4 key molecular biomarkers in gliomas are discussed, including 2 that have been known for some time (1p/19q codeletion and epidermal growth factor receptor [EGFR] amplification) as well as 2 whose relevance was discovered via advanced whole-genome assays (IDH1/2 mutations and BRAF alterations).

Original languageEnglish (US)
Pages (from-to)919-939
Number of pages21
JournalSurgical Pathology Clinics
Issue number4
StatePublished - Dec 1 2012


  • Biomarkers
  • Central nervous system cancer
  • Glioma
  • Molecular pathology
  • Neuro-oncology

ASJC Scopus subject areas

  • Surgery
  • Pathology and Forensic Medicine


Dive into the research topics of 'Something Old and Something New About Molecular Diagnostics in Gliomas'. Together they form a unique fingerprint.

Cite this